The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
EcPLA, also known as N-ethyl-N-cyclopropyllysergamide or as lysergic acid ethylcyclopropylamide (LAEcP), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA. The drug has been encountered as a novel designer drug.
== External links == Media related to Binge eating disorder at Wikimedia Commons Pull, Charles B (January 2004). "Binge eating disorder". Current Opinion in Psychiatry. 17 (1): 43–48. doi:10.1097/00001504-200401000-00008. Binge Eating Disorder on National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
== Principle == In normal-phase chromatography, the stationary phase is polar and the mobile phase is nonpolar. In reversed-phase, the stationary phase is nonpolar and the mobile phase is polar. Typical stationary phases for normal-phase chromatography are silica or organic moieties with cyano and amino functional groups. For reversed phase, alkyl hydrocarbons are the preferred stationary phase; octadecyl (C18) is the most common stationary phase, but octyl (C8) and butyl (C4) are also used in some applications. The designations for the reversed phase materials refer to the length of the hydrocarbon chain. In normal-phase chromatography, the least polar compounds elute first and the most polar compounds elute last. The mobile phase consists of a nonpolar solvent such as hexane or heptane mixed with a slightly more polar solvent such as isopropanol, ethyl acetate or chloroform. Retention decreases as the amount of polar solvent in the mobile phase increases. In reversed phase chromatography, the most polar compounds elute first with the more nonpolar compounds eluting later. The mobile phase is generally a mixture of water and miscible polarity-modifying organic solvent, such as methanol, acetonitrile or THF. Retention increases as the fraction of the polar solvent (water) in the mobile phase is higher. Normal phase chromatography retains molecules via an adsorptive mechanism, and is used for the analysis of solutes readily soluble in organic solvents.
The ancestors of bacteria were unicellular microorganisms that were the first forms of life to appear on Earth, about 4 billion years ago. For about 3 billion years, most organisms were microscopic, and bacteria and archaea were the dominant forms of life. Although bacterial fossils exist, such as stromatolites, their lack of distinctive morphology prevents them from being used to examine the history of bacterial evolution, or to date the time of origin of a particular bacterial species. However, gene sequences can be used to reconstruct the bacterial phylogeny, and these studies indicate that bacteria diverged first from the archaeal/eukaryotic lineage. The most recent common ancestor (MRCA) of bacteria and archaea was probably a hyperthermophile that lived about 2.5 billion–3.2 billion years ago. The earliest life on land may have been bacteria some 3.22 billion years ago. Bacteria were also involved in the second great evolutionary divergence, that of the archaea and eukaryotes. Here, eukaryotes resulted from the entering of ancient bacteria into endosymbiotic associations with the ancestors of eukaryotic cells, which were themselves possibly related to the Archaea. This involved the engulfment by proto-eukaryotic cells of alphaproteobacterial symbionts to form either mitochondria or hydrogenosomes, which are still found in all known Eukarya (sometimes in highly reduced form, e.g. in species of amitochondrial protozoa).
== Analysis == In simple manual columns, the eluent is collected in constant volumes, known as fractions. The more similar the particles are in size the more likely they are in the same fraction and not detected separately. More advanced columns overcome this problem by constantly monitoring the eluent.
Sources: en.wikipedia.org
The stems stay dry through this process to prevent disease in subsequent storage. The major cut flower types can be packaged and stored dry while other types are stored and shipped in water in a Dutch flower bucket. Boxes and pallets of the cut flowers and cut greens are shipped to a far away market, but the brokers and shippers must maintain the correct storage conditions for the flowers. Cut flowers are conditioned upon arrival at a wholesale florist or retail florist. The flowers are removed from the shipment boxes and placed into low pH water in clean buckets to begin hydration. In the same or later step, the stems are cut under water to remove air bubbles from the xylem vessels in the stems and placed into water with a low pH for hydration and bacteria prevention, a biocide (disinfectant) to reduce bacteria and fungi in the water and a type of sugar (often sucrose) to supply energy to the developing cut flowers. The flowers may complete conditioning at room temperature or in a refrigerator depending on the cultivar. Cut flowers and cut greens are kept refrigerated during delivery to the florist or floral designer and to the consumer. Design activities occur at room temperature but floral arrangements are kept refrigerated and hydrated with the floral food solution. Flower vase life can be affected by pre-harvest factors, such as growing conditions, genetic makeup, or post-harvest factors, such as mechanical damage, bacteria or fungi. Vase life also varies across plant species and cultivars.
From the evident difference in the transport of solution and channel appearance, one can identify the separation effect for the determination of blood type. Noiphung et al. at 2014 followed up an approach in paper-based microfluidic blood typing using antibodies to cause red blood cells agglutination, and the group designed a new paper-based analytical device (PAD) for blood grouping that can be used for the synchronous performation of Rh and forward and reverse ABO blood grouping on the same device. Forward grouping is a blood typing procedure whereby patient red blood cells are mixed with Anti-A and Anti-B reagents. On the other hand, reverse typing is a blood typing procedure where patient serum is mixed with reagent A cells and reagent B cells. The results should be the opposite of forward typing. The designed device has two sides: forward (F) side, made of chromatography paper with three channels spotted with 1.5 mL Anti-A, Anti-B, and Anti-D antibody solutions each, and reverse (R) side, made with blood separation membrane and connected to A-type and B-type antibodies channels. The PAD is fabricated using a combination of wax dipping technologies to join Whatman chromatography paper and blood separation membrane. The device included three wax-printed channels for forward grouping, two of which were also applied for reverse grouping. While R-side was capable for whole blood sample analysis, Noiphung's group found that whole blood samples are too viscous to be directly applied on a paper-side of the device.
== Career == In December 1986, Cameron joined the Department of Chemical Engineering at the University of Wisconsin—Madison, as an assistant professor and advanced to full professor. The focus of his research was metabolic engineering (a field now more commonly known as synthetic biology) and industrial microbiology. One of his first projects was the engineering of the microbial pathway for 1,3-propanediol in Escherichia coli. This work was an early step in a process that was eventually commercialized by DuPont and Tate & Lyle. He is also the inventor of a process for the microbial production of 3-hydroxypropionic acid, which provides a bio-based route to industrial chemicals such as acrylic acid. In 1996 he did a sabbatical at the ETH Zurich (Switzerland) in the laboratory of James (Jay) E. Bailey. In 1998 he took a leave of absence to start the Biotechnology Development Center (BioTDC) at Cargill, Inc. in Minneapolis. In 2000 he officially left the University of Wisconsin. Cameron was at Cargill, Inc. from 1998 to 2006, where he was Director of Biotechnology and chief scientist. While at Cargill he worked closely with NatureWorks on the development of a low-pH process for lactic acid as a feedstock for polylactic acid. He and his team also worked with Cargill Ventures on deal-sourcing and due-diligence. In June 2006, Cameron moved from Cargill to join the newly formed Silicon Valley venture capital firm, Khosla Ventures, as chief scientific officer. In 2008, Cameron returned to the Midwest to help Piper Jaffray build and grow its clean tech investment business.
== Recent studies == Recently thermospray was also utilized for the production of semiconductor nanocrystals, analysis of bile acids, identification of dyes, and molecular weight determinations of proteins from multiply charged ions.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.